Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

CorMedix (CRMD) EBIT (2016 - 2025)

CorMedix (CRMD) has disclosed EBIT for 14 consecutive years, with -$59.5 million as the latest value for Q4 2025.

  • Quarterly EBIT fell 290.53% to -$59.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31.5 million through Dec 2025, up 876.32% year-over-year, with the annual reading at $31.5 million for FY2025, 876.32% up from the prior year.
  • EBIT hit -$59.5 million in Q4 2025 for CorMedix, down from $51.3 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $51.3 million in Q3 2025 to a low of -$59.5 million in Q4 2025.
  • Historically, EBIT has averaged -$3.5 million across 5 years, with a median of -$7.8 million in 2021.
  • Biggest YoY gain for EBIT was 1661.93% in 2025; the steepest drop was 290.53% in 2025.
  • Year by year, EBIT stood at -$7.8 million in 2021, then dropped by 7.83% to -$8.4 million in 2022, then dropped by 24.77% to -$10.5 million in 2023, then surged by 398.4% to $31.2 million in 2024, then tumbled by 290.53% to -$59.5 million in 2025.
  • Business Quant data shows EBIT for CRMD at -$59.5 million in Q4 2025, $51.3 million in Q3 2025, and $19.5 million in Q2 2025.